EUVIMEDEUVIMED entdecken
Crossref

Similar Efficacy Observed for First-Line Immunotherapy in Racial/Ethnic Minority Patients With Metastatic NSCLC

Matthew Lee, Jianyou Liu, Emily Miao, Shuai Wang, Frank Zhang, John Wei, Julie Chung, Xiaonan Xue, Balazs Halmos, H Dean Hosgood, Haiying Cheng

Journal of the National Comprehensive Cancer Network · 2023

DOI: 10.6004/jnccn.2023.7064 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the National Comprehensive Cancer Network, 2023. Verfasst von Matthew Lee und 10 weiteren Autor:innen. Beteiligte Einrichtung: 1Department of Medical Oncology, Montefiore Medical Center, Montefiore Einstein Cancer Center, Albert Einstein College of Medicine, Bronx, New York. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 96 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Limited data exist on the impact of immunotherapy use in ethnic minority patients with non–small cell lung cancer (NSCLC), because they have been underrepresented in immunotherapy trials. This study aims to evaluate race/ethnicity and other demographic, socioeconomic, and clinical factors of patients with metastatic NSCLC treated with first-line immunotherapy.

Methods

A retrospective cohort study of 5,920 patients diagnosed with lung cancer treated at Montefiore Einstein Cancer Center from January 1, 2013, to June 1, 2022, was used to identify patients with metastatic NSCLC without EGFR , ALK , or ROS1 alterations who underwent first-line immunotherapy (n=248). The primary endpoint was overall survival (OS), with secondary endpoints of progression-free survival (PFS) and time to discontinuation (TTD) from the start of immunotherapy.

Results

Among the 248 patients, median follow-up time was 12.0 months, median age at start of treatment was 66 years, and 39.1% were non-Hispanic Black, 30.2% were Hispanic, and 30.7% were non-Hispanic White. OS ( P =.39), PFS ( P =.29), and TTD ( P =.98) were similar among racial/ethnic groups. Patients with an ECOG performance status (PS) of

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsHumansEthnicityB7-H1 AntigenRetrospective StudiesEthnic and Racial MinoritiesProtein-Tyrosine KinasesMinority GroupsProto-Oncogene ProteinsImmunotherapy

Stichwörter der Autor:innen

BlacksHealthcare disparitiesHispanicimmunotherapynon-small cell lung cancer

Substanzen

B7-H1 AntigenProtein-Tyrosine KinasesProto-Oncogene Proteins

Autor:innen und Institutionen

  • 1Department of Medical Oncology, Montefiore Medical Center, Montefiore Einstein Cancer Center, Albert Einstein College of Medicine, Bronx, New York.
  • 2Department of Epidemiology & Population Health, Albert Einstein College of Medicine, Bronx, New York.
  • 3Department of Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York.
  • 4Department of Health Information Management, Montefiore Medical Center, Bronx, New York.

Zitieren

APA

Lee, M., Liu, J., Miao, E., Wang, S., Zhang, F., Wei, J., Chung, J., Xue, X., Halmos, B., Hosgood, H. D., & Cheng, H. (2023). Similar Efficacy Observed for First-Line Immunotherapy in Racial/Ethnic Minority Patients With Metastatic NSCLC. Journal of the National Comprehensive Cancer Network. https://doi.org/10.6004/jnccn.2023.7064

Vancouver

Lee M, Liu J, Miao E, Wang S, Zhang F, Wei J, et al. Similar Efficacy Observed for First-Line Immunotherapy in Racial/Ethnic Minority Patients With Metastatic NSCLC. Journal of the National Comprehensive Cancer Network. 2023. doi:10.6004/jnccn.2023.7064

BibTeX
@article{Lee2023,
  author = {Lee, Matthew and Liu, Jianyou and Miao, Emily and Wang, Shuai and Zhang, Frank and Wei, John and Chung, Julie and Xue, Xiaonan and Halmos, Balazs and Hosgood, H Dean and Cheng, Haiying},
  title = {Similar Efficacy Observed for First-Line Immunotherapy in Racial/Ethnic Minority Patients With Metastatic NSCLC},
  journal = {Journal of the National Comprehensive Cancer Network},
  year = {2023},
  doi = {10.6004/jnccn.2023.7064}
}
Kostenlos starten →